Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
87.17
+1.84 (+2.16%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
January 14, 2025
From
Glaukos Corporation
Via
Business Wire
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
January 13, 2025
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
Via
Benzinga
Topics
Fraud
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
December 31, 2024
Via
Benzinga
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
December 23, 2024
From
Glaukos Corporation
Via
Business Wire
How Is The Market Feeling About Glaukos?
December 03, 2024
Via
Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
November 26, 2024
Via
Benzinga
How Is The Market Feeling About Glaukos?
October 30, 2024
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
February 19, 2025
Via
Benzinga
Peering Into Glaukos's Recent Short Interest
February 12, 2025
Via
Benzinga
How Is The Market Feeling About Glaukos?
January 27, 2025
Via
Benzinga
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
January 23, 2025
Via
Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
What 11 Analyst Ratings Have To Say About Glaukos
December 31, 2024
Via
Benzinga
(GKOS) - Analyzing Glaukos's Short Interest
December 26, 2024
Via
Benzinga
A Closer Look at 7 Analyst Recommendations For Glaukos
October 14, 2024
Via
Benzinga
Navigating 11 Analyst Ratings For Glaukos
August 28, 2024
Via
Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 17, 2024
From
Glaukos Corporation
Via
Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
December 07, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.
Via
Talk Markets
Topics
Stocks / Equities
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
December 06, 2024
Via
Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
December 02, 2024
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via
Benzinga
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
August 01, 2024
Via
Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
December 02, 2024
Via
Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
November 08, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
November 05, 2024
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.
Via
Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
November 04, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
October 16, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
October 14, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
October 09, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
August 16, 2024
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.